U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07118670) titled 'High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes' on July 29.
Brief Summary: The purpose of this Phase 4 study is to evaluate the safety of aflibercept 8mg in patients with proliferative diabetic retinopathy without center-involved diabetic macular edema.
Study Start Date: Aug. 31
Study Type: INTERVENTIONAL
Condition:
Proliferative Diabetic Retinopathy (PDR)
Intervention:
DRUG: Aflibercept 8mg
Solution in Vial, intravitreal (IVT) injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Edward Wood, MD
Information provided by (Responsible Party): Edward Wood, MD, Greater Houston Retina Research
Disclaimer: ...